12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Amitiza lubiprostone regulatory update

Sucampo and Takeda submitted an sNDA to FDA for Amitiza lubiprostone to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain. The partners requested Priority Review. Sucampo and...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >